Exclusive extracts from this 114-page-long report:
- What is the business?
The pharmaceutical industry, which generated over 1 trillion euros in revenues worldwide in 2017, is a highly fragmented and diversified sector that weighs heavy in terms of GDP contribution, research spending and employment. Leading pharmaceutical companies engage in a great variety of activities ranging from research and development to drug testing, manufacturing, and marketing. […]
- What are the main markets?
Mature economies still account for the bulk of global pharmaceutical revenues. Nevertheless, increasing wealth, larger populations, improving access to healthcare and growing rates of lifestyle diseases will put emerging countries ahead of developed markets in terms of long-term healthcare and pharmaceutical spending growth. Major emerging pharma markets will see their share in global pharma revenues nearly double in the decade between 2010 and 2020. [...]
- Who are the key players?
The pharmaceutical industry remains relatively fragmented despite recent years' wave of consolidation that has seen big pharma groups focus on acquisitions to adapt to an increasingly challenging market environment. Mature-market players continue to rule the industry, with US, European and Japanese players occupying the industry's top spots. However, emerging market drug companies have gained global market share in recent years amid growing opportunities in their home markets. [...]
- How intense is competition?
Competitive pressure in the pharmaceutical industry has increased in the context of a wave of major drug patent expirations, increased competition from generic drugs, stricter regulation, and slowing innovation. As a result, pharma companies have seen their returns slow and shareholder pressure increase, forcing them to seek new ways to improve operating efficiency, enhance competitiveness and boost returns. [...]